Drug Hunter
Andres has over 10 years of finance and operations experience working with public and private life science companies. He currently serves as Vice President, Head of Business Operations and Investor Relations at IDEAYA Biosciences, Inc. (NASDAQ: IDYA). Prior to joining IDEAYA, Andres was at Pharmacyclics, Inc., (NASDAQ: PCYC) where he helped lead the organization’s finance and operations efforts in support of the successful launch of blockbuster cancer drug, IMBRUVICA (ibrutinib) and played a key role in building the Company’s long-range planning and the integration activities into AbbVie, following Pharmacyclics’ $21 billion acquisition. Prior to that, Andres held roles at Theravance, Inc. (NASDAQ: THRX), and at PricewaterhouseCoopers’ audit and assurance practice where he focused on life science and venture capital clients.
Andres obtained his B.S. in Business Administration with a concentration in Corporate Financial Management from San Jose State University and is a Certified Public Accountant, licensed in the state of California.
This person is not in the org chart
This person is not in any offices
Drug Hunter
Drug Hunter is a dependable, impartial source of fact-checked information for the community of drug researchers. Professionals involved in drug discovery can use it to save time, keep updated, and generate ideas. The biotech and pharmaceutical sectors, in addition to the research and individuals that work in them, are celebrated by them. They maylocate new partners, drug discovery activities, professional opportunities, and other resources. They collaborate with companies that have creative innovations and beneficial materials to offer R&D executives.